2 of the algorithm details the combination options of the different drug classes
PlexusDx also offers GLP-Squared, a dual-compound injection combining semaglutide and tirzepatide in a single formulation, at $289/mo month-to-month, or from $249/mo on the 6-month plan

Obesity and diabetes represent converging epidemiological crises: Fleur Pitch Semifinal for the McCloskey New Venture Competition The existing therapeutic arsenal demonstrates significant shortcomings across multiple dimensions: Mechanism: Increases insulin sensitivity and decreases hepatic glucose production Limitations: High consumption rate leading to digestive system stress, diarrhea, lactic acidosis, and vitamin B12 deficiency Mechanism: GLP-1 receptor agonists that stimulate insulin release and slow gastric emptying Limitations: Weekly injections, extended systemic half-life, neurological side effects including brain fog, optic nerve complications, depression, anxiety, and ADHD-related symptoms Mechanism: Direct insulin replacement therapy Limitations: Daily dosage requirements, off-peak effects where insulin affects blood sugar at suboptimal times Mechanism: Promotes glucose excretion through urine Limitations: Risk of urinary tract infections and dehydration Current injectable treatments represent a significant financial burden, with monthly costs ranging from $886 to $1,349: This pricing structure places effective treatment beyond the reach of many individuals who would benefit most from therapeutic intervention

Another study by Truveta Research compared Mounjaros and Ozempics active ingredients in overweight and obese adults
doi: 10.1007/s00198-018-4581-y 17 DriessenJHvan OnzenoortHAHenryRMLalmohamedAvan den BerghJPNeefCet al